Istesso announces FDA Fast Track and Orphan Drug designation for MBS2320
Istesso Limited, the programmed disease resolution company, today announces that...
5th December 2022
MBS2320 administered to participants with moderate-to-severe Rheumatoid Arthritis
Istesso Limited, the programmed disease resolution company, today announces the...
6th September 2022
Potential of Istesso’s MBS2320 hits the headlines
Istesso Limited (“Istesso’’) was featured on Thisismoney.co.uk over the weekend,...
30th August 2022
MBS2320 Phase 2a headline results announced
Istesso Limited (“Istesso’’) today announces headline results from the Phase...
15th July 2019
Istesso adds a further £4 million to fundraise
Istesso Limited (“Istesso’’) today announces that it has completed a...
1st February 2019
Istesso completes £6 million fundraise
Istesso Limited (“Istesso’’) today announces that it has closed a...
12th December 2018
New appointment of non-executive directors
Istesso Limited (‘’Istesso’’) is pleased to announce the appointment of...
20th September 2017
Positive outcome from Phase 1 study of MBS2320
Istesso announces positive outcome from patient cohort in Phase 1...
30th August 2017